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Non-AUG start codons responsible 
for ABO weak blood group alleles 
on initiation mutant backgrounds
Emili Cid1,*, Miyako Yamamoto1,* & Fumiichiro Yamamoto1,2
Histo-blood group ABO gene polymorphism is crucial in transfusion medicine. We studied the activity 
and subcellular distribution of ABO gene-encoded A glycosyltransferases with N-terminal truncation. 
We hypothesized that truncated enzymes starting at internal methionines drove the synthesis of 
oligosaccharide A antigen in those already described alleles that lack a proper translation initiation 
codon. Not only we tested the functionality of the mutant transferases by expressing them and 
assessing their capacity to drive the appearance of A antigen on the cell surface, but we also analyzed 
their subcellullar localization, which has not been described before. The results highlight the importance 
of the transmembrane domain because proteins deprived of it are not able to localize properly and 
deliver substantial amounts of antigen on the cell surface. Truncated proteins with their first amino 
acid well within the luminal domain are not properly localized and lose their enzymatic activity. Most 
importantly, we demonstrated that other codons than AUG might be used to start the protein synthesis 
rather than internal methionines in translation-initiation mutants, explaining the molecular mechanism 
by which transferases lacking a classical start codon are able to synthesize A/B antigens.
Histo-blood group ABO system consists of oligosaccharide A and B antigens and the antibodies against those 
antigens. Because these glycan antigens are expressed not only on red blood cells (RBCs), but also on epithelial and 
endothelial cells, matching the ABO blood groups is critical for safe blood transfusion and transplantation of cells, 
tissues and organs. Since its molecular elucidation in 19901,2, numerous alleles at the human ABO genetic locus 
have been identified and characterized, and this locus has become one of the best-studied loci for genetic poly-
morphism and heterogeneity. The updated list of ABO gene alleles may be found in the Blood Group Antigen Gene 
Mutation Database (http://www.ncbi.nlm.nih.gov/gv/rbc/xslcgi.fcgi?cmd= bgmut/systems_info&system= abo)3. 
There are three major alleles: A (A1) alleles that encode N-acetyl-d-galactosaminyltransferases (histo-blood 
group A transferases), B alleles that encode d-galactosyltransferases (B transferases), and non-functional O 
alleles. Both the A and B transferases utilize the same acceptor substrate H (Fucα 1-2Gal-), and transfer by the 
same α 1,3-glycosidic linkage an n-acetyl-d-galactosamine (GalNAc) and a galactose (Gal) to synthesize oligosac-
charides A and B antigens, GalNAcα 1-3(Fucα 1-2)Gal- and Galα 1-3(Fucα 1-2)Gal-, respectively. The O proteins 
possess neither activities, and H substance remains without further modifications.
In addition to those 3 alleles, there are additional alleles that specify weak expression of A or B antigens (phe-
notypically called as A2, A3, Aweak, Ael, B3, Bel, etc.). The molecular mechanisms responsible include mutations 
in the promoter/enhancer regions of the ABO gene that cause a reduction in gene transcription, mutations in 
the splicing donor/acceptor sequences that cause inefficient splicing of correct messages, and mutations in the 
coding sequences resulting in structural deficiencies of the A/B transferases. In the last category, the majority of 
the mutations were identified in the catalytic domain of the coding sequences. Together with the determination 
of the three dimensional structures of the human A and B transferases4 and in vitro characterization of A and 
B transferases with mutations1,5, many of the non-synonymous mutations that were found present in the A/B 
subgroup alleles proved to be useful in characterizing the structure bases of specificity and activity of the A and 
B transferases. Although less frequent, a priori different group of weak alleles also exist. In this group, structural 
changes outside of the catalytic domain were identified. Those include initiation codon missense mutations (M1V 
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in an Aweak allele, for instance) and nonsense mutations causing an early termination (E3X and R18X in Ael and 
Bel alleles)6–8.
We previously assessed the functionality of the A gene transcript starting from the alternative exon 1a9. The 
exon 1a does not contain an ATG codon, however, the transcript led to the expression of A antigens, suggesting 
that an internal codon was used for the initiation of translation. We also prepared a variety of expression con-
structs encoding N-terminally truncated A transferases with a deletion of the cytoplasmic tail and/or a portion/
whole of the transmembrane (TM) domain, and analyzed their enzymatic activities. Several of the constructs 
exhibited the appearance of A antigens on the transfected human cells expressing cell-surface H substances 
although the abundance of A antigens was very small. Analyzing the effects of a translation-initiator mutation, a 
separate study by others showed that the mutation causes the Aweak phenotype6.
In spite of the fact that those studies delineated the significance of N-terminal domain(s) for the full activities 
of A and B transferases to produce large amounts of cell-surface A and B antigens, the subcellular localization 
of the proteins encoded by the respective constructs was not revealed. No clear answer was available explaining 
how some polymorphic alleles, without methionine 1 or a stop codon right after, were able to be translated. 
We re-visited the structure-function correlation of the N-terminally truncated A transferase proteins because 
intra-Golgi localization of the A and B transferases is vital for the biosynthesis of those oligosaccharide antigens. 
We examined the presence/absence of co-localization of those proteins with a Golgi marker protein derived from 
β 1,4-galactosyltransferase 2 encoded by the B4GALT2 gene and also with GOLGA2, a Golgi-resident protein. 
The results demonstrated that the N-terminal domain of A/B transferases might play a crucial role in the pro-
tein folding and in-Golgi localization of these clinically relevant transferases. Furthermore, during the course of 
investigation, we observed that a mutant A transferase construct having methionine to threonine substitutions 
at codons 1, 20, 26, 43, 53, and 69 induced the production of A antigens on transfected cells. Affinity purification 
and N-terminal sequencing of the protein demonstrated that the A transferase was translated using an unconven-
tional non AUG-codon for initiation.
Results
Construction of A transferase N-terminal deletion mutants. We first created a series of A transferase 
N-terminal deletion constructs starting at each internal methionine in order to explain the capacity of these 
methionines to act as start codons when their upstream initiation was impaired, due to missense mutations or 
early termination. The predicted topology of the protein is shown in Fig. 1: amino acids 1 to 32 correspond to 
the cytoplasmic tail, 33 to 53 to the transmembrane domain and the rest of the protein is located in the Golgi 
lumen as indicated by the annotation in public protein databases (http://www.uniprot.org/uniprot/P16442). All 
the methionines present within the N-terminal half of the protein are represented as filled circles and numbered 
according to their position.
Using an A1 allele (A101) as template, the truncated open reading frames were PCR-amplified and cloned 
into pSG5. We also created their C-terminal myc-tagged versions to study their subcellular localization. A sche-
matic representation of the resulting constructs made, Δ 19, Δ 25, Δ 42, Δ 52, Δ 68 and Δ 141, is also shown. The 
nomenclature is based on the amino acids deleted at the N-terminal of A transferase. For instance, Δ 19 con-
struct encodes for a protein lacking the amino acids 1–19 and starting at methionine at codon 20. We also con-
structed three more mutants starting within the lumenal portion of the protein, Δ 95-W96M, Δ 112-N113M and 
Δ 122-I123M. These deletion mutants have a newly introduced methionine (M) start codon; each one starts right 
after eliminating secondary structure features of the globular domain as shown in the crystal structure4. They start 
after two β strands, β 1 (82–84) and β 2 (93–95) for Δ 95-W96M, after α helix 1 (102–111) for Δ 112-N113M, and 
after β 3 strand (115–122) for Δ 122-I123M. We also subcloned in the same vector the inactive allele O1 which is 
identical to the A101 allele except for the G261 nucleotide deletion.
Preparation of FUT2 stably expressing cells and assessment of A antigen presence on cell mem-
brane. In order to maximize the synthesis of A antigen by A transferases with non-optimal catalytic activity, 
we modified HeLa cells to overexpress α 1,2-fucosyltransferase encoded by FUT2 gene, and created HeLa FUT2 
cells, following an strategy developed in the laboratory10. The expression of FUT2 increased the availability of the 
H substance, the precursor to A and B antigens.
All the constructs shown in Fig. 1a were transiently transfected in those cells. After 72 h, the cells were fixed 
and subjected to immunocytochemistry against A antigen. Positive staining only appeared on cells transfected 
with A transferase construct, the truncated mutants Δ 19, Δ 25, Δ 42, Δ 52, and Δ 68 as marked by positive 
signs in Fig. 1. On the contrary, Δ 95-W96M, Δ 112-N113M, Δ 122-I123M, Δ 141 and O1 were all negative (see 
Supplementary Figure SF1 for representative images of stained cells). The ABC protocol for immunocytochemis-
try used consists of a streptavidin-biotin complex conjugated to an enzyme producing the chromogenic reaction. 
The amplifying nature of the staining procedure prompted us to examine another method to assess the capacity 
of each mutant to produce A antigen on the cell surface in a more quantitative manner. We also wanted to assay 
this capacity in a shorter time window in order to avoid product accumulation, which would not reflect enzymatic 
capacity adequately.
Measurement of A antigen production by cytometry. We subcloned the deletion mutants that showed 
positive staining into a retroviral vector containing an IRES (Internal Ribosome Entry Site) sequence followed by 
GFP (Green Fluorescent Protein). HeLa FUT2 cells were transiently transfected with these retroviral constructs 
as well as Δ 141, which showed no activity. Only those cells exhibiting green fluorescence were expressing the A 
transferase constructs. Around 32 h post transfection, cells were detached with 5 mM EDTA and washed exten-
sively with PBS and stained with monoclonal anti-A antigen antibody followed by AlexaFluor 647-conjugated 
anti-mouse IgM secondary antibody and analyzed by cytometry (36 h post-transfection).
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Two different controls to test the secondary antibody background and the specificity of anti-A staining were 
used: cells transfected with an empty vector expressing only GFP not stained with any primary antibody and cells 
expressing A transferase treated with anti-B antibody as a suitable isotype antibody control. A third control was 
added and included in all the analysis: cells transfected with the empty vector, therefore expressing only GFP and 
treated with anti-A and secondary antibodies, which accounts for the background fluorescence of the primary 
antibody used. The same detection settings were used for all the following experiments. Forward and side scatter 
values were used to select the viable single cell population and the fluorescence at 550 nm corresponding to GFP 
to select those cells expressing the transgenes.
Figure 2a is a superimposition of histograms corresponding to the fluorescence at 660 nm for all the samples 
analyzed. The anti-B antibody and secondary antibody only controls showed no fluorescence. Cells transfected 
Figure 1. Schematic representation of the blood group A transferase coding sequence and protein. (a) 
Blood group A transferase is shown schematically. Numbers correspond to amino acid positions. Black circles 
are the methionines present in the N-terminal half of the enzyme. “Cyto” correspond to cytoplamic tail, and 
“TM” to transmembrane domain of the enzyme. The latter is also shown as a gray area. The “Lumenal” portion 
corresponds to the protein domain residing inside the Golgi. On the right column, “A staining” corresponds to 
the immunocytochemistry results. Plus sign (+ ) corresponds to a positive detection of A antigen and minus 
(− ) a negative result. The different mutant construct protein products are depicted below. Δ 19 corresponds to 
a deletion mutant starting at methionine 20 and therefore without amino acids 1 to 19. We named the following 
ones Δ 25, Δ 42, Δ 52, Δ 68 and Δ 141 similarly. The Δ 95-W96M lacks also 1–95 and starts in a newly created 
methionine at position 96 by introducing the missense mutation W96M. The same naming scheme was used 
for Δ 112-N113M and 122-I123M. The O1 corresponds to the O101 allele product. The crisscrossed area 
represents the additional amino acid stretch of frame-shifted reading frame after the nucleotide G261 deletion. 
(b) The myc-tagged A transferease and its threonine mutants are shown schematically. Solid squares represent 
introduced mutations, ATG → ACG exchanging methionine for threonine, in the indicated locations. The 
nucleotide sequence at 5′ of the first amino acid (M or T) is also shown. The small bars on top show in-frame 
STOP codons. At the C-terminal both the nucleotide and amino acid sequences corresponding to the myc-tag 
fragment are shown.
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with empty vector presented a level of 660 nm fluorescence similar to the inactive Δ 141 sample. In contrast, A 
construct is highly positive, as is Δ 19; after that the fluorescence decreases gradually for the remaining mutant 
constructs.
For each experiment, we measured the median red fluorescence at 660 nm of A antigen-positive cells, defined 
as those above the background level, for each construct. The means of the medians are shown in Fig. 2b. As 
expected, non-truncated A transferase gave the highest values. Regarding the truncated mutants, Δ 19 and Δ 24, 
while still conserving the transmembrane domain, showed diminished but clear capacity to produce A antigen 
when transfected into HeLa FUT2 cells (42% and 12% of the A median fluorescence, respectively). Once the 
truncation spanned most, or all, of the TM domain as of the truncated mutants, Δ 42, Δ 52 and Δ 68, the capacity 
to produce surface A antigen drastically diminished. However, their enzymatic activity is not null. Although no 
statistically significant differences were found between those constructs and the empty construct control, they 
have higher median values than the background. Furthermore, clearly positive A staining was observed with 
those constructs by immunohistochemistry where signal is amplified (Supplementary Figure SF1). Finally Δ 141, 
with a truncation well within the lumenal portion, and hence in the catalytic portion of the enzyme, showed no 
antigen production on the membrane and its fluorescence median is practically identical to the empty control. 
This is a real null construct, and no A antigen expression was observed even by the more sensitive immunohis-
tochemical method.
We repeated the fluorescent measurements at 60 h post-transfection. Results were similar, but cells transfected 
with original A transferase seem to have lost some fluorescence intensity. This may reflect protein turnover or cell 
death due to overexpression of the enzyme or its product. The rest of constructs show a very similar behaviour 
as in the 36 h experiment. Again only those constructs showing substantial activity (A, Δ 19) are statistically dif-
ferent from the empty control although the others (except for Δ 141) consistently showed higher median values 
than the background.
Figure 2. Cytometry analysis of A antigen synthesis capacity. (a) HeLa FUT2 cells transfected with A 
transferase constructs were selected by increased 530 nm fluorescence from the global population as seen in 
the upper inset. The composite histogram shows the 660 nm fluorescence of those cells corresponding to the 
presence of A antigen by detection of a secondary antibody conjugated to Alexa647 binding in turn to an anti-A 
antigen antibody. The “Secondary” histogram corresponds to A transferase transfected cells treated without 
primary antibody, the “α B” to the same cells treated with anti-B antibody instead of anti-A antibody. The rest 
of cells were stained both with anti-A and the secondary antibody. The “Empty” graph shows the staining 
of cells transfected with an empty vector, “A” with the A transferase construct, and further on. The X-axis 
shows fluorescence at 660 nm on an exponential scale. The height of the graph corresponds to the number of 
cells for each fluorescence value. (b) The median of 660 nm fluorescence is shown of each construct from five 
independent experiments after 36 h post-transfection. ***P < 0.001, *P > 0.05 assigned by the Duncan test. The 
inset graph shows the mean of the 660 nm/530 nm fluorescence for each data point. (c) The median of 660 nm 
fluorescence after 60 h post transfection. ***P < 0.001, **P > 0.01.
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Inset graphs in Fig. 2b and c show the median for the 660 nm/530 nm fluorescence ratio. It is a measure of the 
“efficiency” of the protein to produce antigen. The expression of GFP (measured by the fluorescence emission at 
530 nm), is concordant with the expression of the construct as it is the result of the IRES sequence on the same 
transcript, and therefore, it is an indication of the level at which the A transferase is transcribed. For a given 
amount of transcribed protein, cells transfected with full A transferase construct exhibited 24 times more fluo-
rescence intensity at 660 nm than with Δ 25, while Δ 19 had an intermediate value of 9.4 at 36 h post-transfection. 
At longer time of 60 h, this “efficiency” becomes similar between A and Δ 19 (14 vs. 17) due to the accumulation 
of A antigen.
Subcellular localization of N-terminal truncated A transferases is crucial to their antigen syn-
thesis ability. We also wanted to determine the intracellular localization of the mutant proteins to corre-
late their activity with their presence in the Golgi apparatus. First we created a Golgi-targeted GFP (GTS-GFP) 
marker by fusing the first 60 amino acids of the B4GALT2 encoded β 1,4-galactosyltransferase 2 to the N-terminus 
of GFP. We subcloned this open reading frame in the pRK5 vector. The transient expression in HeLa FUT2 cells 
showed perinuclear distribution typical of the Golgi apparatus as seen in Fig. 3 (GTS-GFP panels).
The localization within the cell of the myc-tagged N-terminally truncated proteins present great differences 
as it is shown in Figs 3 and 4. Non-truncated myc-tagged A transferase exhibits a clear colocalization with the 
Golgi marker; the overlap can be appreciated in yellow in the merged images. It also shows signal in other cellular 
Figure 3. Subcellular localization of overexpressed active A transferase internal methionine deletion 
mutants. HeLa FUT2 cells were transfected with A transferase mutants able to produce A antigen as detected 
by immunocytochemistry. Lipofectamine 2000 was used. A Golgi-targeted GFP, GTS-GFP, was co-transfected. 
Single optical slice images were taken using confocal microscopy. Anti-myc (α myc in the top panel) shows the 
signal from myc-tagged proteins detected with a primary anti-myc antibody followed by secondary Alexa568-
anti mouse IgG antibody. The merged images are colour coded red for myc-tagged proteins and green for 
GTS-GFP, showing colocalization in yellow. Zeiss ZEN software was used to determine the colocalization 
factor values between the α myc signal detecting the protein and GTS-GFP marking the Golgi apparatus for 
each image. More than 50 images were analyzed from four independent experiments. The values obtained were 
plotted using R software as boxplots.
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structures reflecting the dynamic distribution of the enzyme. The Golgi localization of the myc-tagged proteins 
was quantified using confocal microscopy by measuring their degree of colocalization with GTS-GFP. The median 
of the colocalization coefficient of anti-myc (α myc) signal with GTS-GFP signal for each construct is shown as a 
boxplot in Fig. 3. The colocalization is the same for the whole enzyme (0.24) and Δ 19 (0.24). On the other hand, 
Δ 25, although with a higher variability, already shows a lowered Golgi localization, similar to Δ 42 (0.13 both). In 
the case of Δ 42, its transmembrane domain has been truncated (only about half of it remains: the last 12 amino 
acids out of 22) but it is still able to localize, albeit partially, in its intended compartment. Regarding Δ 52 and 
Δ 68, the former has only two amino acids of the transmembrane region, which is clearly not sufficient for tar-
geting the protein to the Golgi and, as Δ 68, does not colocalize at all with GTS-GFP (0.09 and 0.06 respectively), 
clearly being illustrated in the merged picture where no yellow signal is present. Moreover, Δ 52 and Δ 68 show 
a more homogenous distribution throughout the cell, a pattern compatible with a typical cytoplasmic soluble 
protein. The complementary data, that is, the colocalization coefficient of GTS-GFP vs. α myc signal is constant 
for all samples and very close to 1. This indicates that there is always red signal together with green, or in other 
words, there is always overlapping.
Figure 4 shows the subcellular localization of the inactive N-terminally truncated proteins together with 
the Golgi marker GTS-GFP. Δ 141, the last initiation methionine mutant, and in contrast with all the others, 
is completely inactive. As it starts well within the lumenal portion of the protein, it has lost important struc-
tural features of the catalytic domain. Furthermore, the tagged protein signal showed bigger aggregation. This 
aberrant localization is accompanied by an increased overlap with GTS-GFP, contrasting with the soluble local-
ization of Δ 52 and Δ 68 myc-tagged proteins (0.26). We have also evaluated the subcellular distribution of 
Δ 95-W96M, Δ 112-N113M and Δ 122-I123M mutants that, even though they do not represent transcripts initi-
ated by any internal methionine, they would add more information about the dependence of the protein distribu-
tion on the N-terminal domain length. The first two, Δ 95-W96M and Δ 112-N113M, showed an apparent nuclear 
Figure 4. Subcellular localization of overexpressed inactive A transferase internal methionine deletion 
mutants. HeLa FUT2 cells were transfected with A transferase mutants that are unable to produce A antigen as 
detected by immunocytochemistry. The same experimental conditions described above in the legend of Fig. 3 
were used for DNA transfection and fluorescence detection.
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accumulation. The nuclear distribution was accompanied by some cytoplasmic aggregation of the fluorescent 
signal and an intermediate degree of colocalization with GTS-GFP (0.13 and 0.16). The last mutant Δ 122-I123M 
behaved similarly as Δ 141 and showed enhanced colocalization with GTS-GFP (0.20). The upper panel shows 
the colocalization coefficient of GFP-GTS vs. α myc signal. It is also close to 1 for Δ 95-W96M and Δ 112-N113M, 
as in the case of active mutants, while Δ 122-I123M and Δ 141 mutants had reduced colocalization (0.66 and 0.74 
respectively). The last two also showed increased aggregation of the myc signal.
As these experiments were performed using a CMV promoter and transient transfection conditions, we were 
concerned that some of these subcellular patterns, especially the aggregation, were due to a high level of overex-
pression. Therefore, we also stably transduced HeLa FUT2 cells with these myc-tagged mutants in a viral vector 
and analyzed their subcellular localization avoiding such overexpression. The results are shown in Fig. 5. The 
Golgi apparatus was detected using an antibody against the resident protein GOLGA2. All myc-tagged proteins 
presented a speckled pattern when detected using anti-myc antibody. The colocalization quantification shown 
in the upper panel also showed that the overlapping between the myc and the Golgi signals decreased as the 
N-terminal deletion increased. The weighted colocalization median of α myc against GOLGA2 for each construct 
are as follows: 0.156 (A), 0.075 (Δ 19), 0,04(Δ 25), 0.023(Δ 42), 0.029 (Δ 52), 0.03 (Δ 68), 0.00 (Δ 95-W96M, 
Δ 122-I123M and Δ 141), 0.01 (Δ 112-N113M). The images show greater expression and a clear colocalization 
(in yellow) of A-myc and Δ 19-myc with the Golgi marker, while all the others present lower or no colocalization 
at all. Furthermore, the expression of these other mutants appears to be lower. The STOP-T-mutant quantification 
indicates some colocalization but we believe that the decreased expression of these proteins makes their detection 
and therefore their colocalization measurements more difficult. Images for the myc-tagged proteins A, Δ 19, Δ 52 
and STOP-T-mutant are shown at the bottom of Fig. 5. A representative image for each mutant can be found in 
Supplementary Figure SF2. The O1 mutant showed reduced Golgi localization (0.14 in Fig. 4 and 0.013 in Fig. 5) 
when compared to A transferase.
A mutant lacking Met 1 start codon is translated using a non-AUG codon. Next, we wanted to 
compare the capacity of the truncated enzymes with the product of the A-M1,20,26,43,53,69 T mutant, which 
possesses the methionine to threonine substitutions at codons 1, 20, 26, 43, 53, and 69. The latter was reported 
to produce A antigen in transfected cells6 and we corroborated it by transfection and immunocytochemistry by 
DAB staining. By cytometry it showed a level of median fluorescence close to the unmodified A allele or Δ 19 
(a 58% of A median fluorescence). In order to exclude the possibility of an upstream 5′ start codon we introduced 
Figure 5. Subcellular localization of stably transfected A transferase mutants. HeLa FUT2 cells were 
stably transfected with A transferase mutants by retroviral infection and FACS selection. Single optical slice 
images were taken using confocal microscopy. Anti-myc shows the signal from myc-tagged proteins detected 
with a primary anti-myc antibody followed by secondary Alexa568-anti mouse IgG antibody. Golgi protein 
GOLGA2 was detected using a rabbit anti-GOLGA2 antibody followed by secondary Alexa647-anti rabbit IgG 
antibody. The merged images are colour coded green for myc-tagged proteins and red for GTS-GFP, showing 
colocalization in yellow. Zeiss ZEN software was used to determine the colocalization factor values of the anti-
myc signal detecting the tagged protein and GOLGA2 marking the Golgi apparatus. Representative images of 
four of the constructs are shown. At least 50 cells were analyzed per construct. The values obtained were plotted 
using R software as boxplots.
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a closer in-frame STOP codon right before the threonine at position 1. The resulting construct was also positive 
for A staining. These proteins are schematically represented in Fig. 1b. We decided to investigate the molecular 
weight of the protein responsible for the A antigen appearance. The Western blot against myc (from now on myc) 
detecting the myc-tagged versions of the N-terminal deletion enzymes, including A-M1,20,26,43,53,69 T and 
STOP-A-M1,20,26,43,53,69 T, is shown in Fig. 6a. The deletion mutants have smaller sizes than A transferase as 
expected. On the other hand, the proteins produced by the two threonine mutants described above are identical 
in size and indistinguishable from the unmodified enzyme.
In order to know which initiation codon was used to translate a protein of this size in the absence of any methio-
nine codon at the N-terminal region, we turned to protein N-terminal sequencing. To do that, HeLa FUT2 cells 
were infected with retroviral vectors encoding the myc-tagged versions of A and A-STOP-M1,20,26,43,53,69 T 
mutant followed by an IRES sequence and GFP. Stable transformants were selected and seeded as single cells in 
96 well plates. Individual clones were grown and tested by immunoblotting for high expression of the proteins. 
The clones with highest myc/tubulin ratio were selected and expanded. Cellular extracts were subjected to affinity 
chromatography with agarose coupled to anti-myc monoclonal antibody and eluted with the myc peptide. The 
purified proteins were then blotted onto PVDF membrane and stained with Ponceau S. The band correspond-
ing to the M1,20,26,43,53,69 T mutant and control A transferase were excised and sequenced by an automated 
protein sequencer. The results, plotted in Fig. 6b, indicated that the mutant protein started with alanine-glutamic 
acid-valine-leucine (AEVL), which correspond to amino acids 2 to 5 of the A transferase protein, exactly the 
same as the unmodified A protein (see Supplementary Data SD1 for the complete N-terminal protein sequencing 
results). Therefore, the translation machinery was able to use the ACG triplet at Thr 1 to start translation from the 
same location as the wild type enzyme.
Discussion
We were interested in finding out a possible molecular mechanism explaining the presence, albeit reduced, of A 
or B antigen in ABO alleles with the translation on initial methionine codon disrupted by missense mutations 
Figure 6. Determination of the translation start site of the threonine substitution mutant. (a) HeLa FUT2 
cells were transfected with the myc-tagged versions of A transferase (A, Δ 19, Δ 25, etc.), A-M1,20,26,43,53,69T-
myc mutant (T mutant), and the same construct with an in-frame STOP codon at 5′ of the first threonine 
(A-STOP-M1,20,26,43,53,69T-myc denoted as STOP-T mutant in the figure). Cell extracts were subjected 
to SDS-PAGE (10% polyacrylamide) and blotted onto PVDF membrane. Signals were obtained using a 
monoclonal anti-myc antibody followed by horseradish peroxidase-linked anti-mouse IgG antibody incubation 
and enhanced chemiluminescence reagent. Signals were detected on chemiluminescence sensitive film. The 
numbers indicate the sizes and positions of molecular weight markers in kDa. (b) The N-terminal sequence 
chromatograms obtained by the Procise 494 analyzer are shown for A-STOP-M1,20,26,43,53,69T-myc. In each 
cycle the major amino acid detected has been marked by an arrowhead and its one-letter symbol.
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or by early termination codons in the 5′ end of the coding sequence. Different alleles of these kind have been 
described: Aw13 (2 T > C) M1T with initiator methionine codon disrupted specifying an Aw phenotype6 or A309 
(1 A > G) M1V producing an A3 phenotype8. The same authors described the early termination mutations R18X 
and E3X (on B allele) that were associated with the weak phenotypes Ael and Bel, respectively, and hypothesized 
that N-terminally truncated enzymes translated from remaining internal methionines were responsible for the 
antigen presence.
We tested this hypothesis and analyzed if proteins starting at internal methionines were able to synthesize the 
antigen. This had been investigated before as the catalytic activity of these truncated proteins was measured in 
homogenates9. However, in the work described here we also studied the subcellular localization of these deletion 
mutants. The first truncated protein Δ 19 and full-length A transferase were similarly located within the Golgi 
apparatus but Δ 19 produced less A antigen on cell surface. We are not sure if that is the result of a decreased 
activity although its “efficiency” ratio might indicate that. Δ 25 still contains a complete transmembrane domain 
and exhibits significant activity and an intermediate level of Golgi localization. These results further stress the fact 
that a complete TM and lumenal domains are necessary for a substantial A antigen presence on the membrane. 
In previous reports6,9, the transmembrane domain was assumed to be situated between amino acids 17 and 37. 
Therefore, Δ 25 was considered to be a mutant in the “stem region” while more recently the TM region is being 
localized at 33–53, leaving Δ 25 as a Golgi-located mutant as our results corroborate. Δ 42 seems to be a special 
case, conserving only about half of the TM domain. It is still localized in Golgi, at a similar level as Δ 25, but in 
contrast, it is not able to deliver a significant amount of A antigen indicating both the crucial role of exon 3 (which 
codifies for the 90% of the TM domain) and the fact that interfering with subcellular localization signals is deter-
minant for altered glycosyltransferase activity. The importance of exon 3 in antigen production can be further 
emphasized by other reports. For example, Cai et al.8 found that the conservative R40K missense mutation in 
the TM region results in an Ax phenotype (mainly characterized by minimal amount of A antigen in saliva and 
detected by hemagglutination with anti-A,B but not with anti-A antibodies).
Hata et al.9 examined A transferase activity for Δ 52 and Δ 68 constructs in an in vitro enzymatic assay utilizing 
transfected cell extracts, 14C-radiolabeled UDP-GalNAc, and 2′ -fucosyllactose. Both constructs showed specific 
activities in the range of the wild type enzyme demonstrating that the catalytic activity was not affected. The fact 
that this work was not able to detect surface antigen by cytometry in a statistically significant amount could be 
the result of its incorrect localization as shown by our microscopy experiments. Even though they conserve enzy-
matic capacity, they do not biosynthesize a considerable amount of antigen, as they require access to substrates 
at appropriate concentrations. The lack of proper pools of UDP-GalNAc and H substance in the cytosol and 
improper localization of the protein greatly limit the ability of this enzymes to transfer GalNAc to H substance. 
However, a very minor fraction of the protein may enter the Golgi apparatus and we believe that this fraction may 
be the one responsible for the small amount of antigen present on the cell surface.
Δ 141 is completely inactive. No specific activity for this protein was found by Hata and colegues9, coinciding 
with our results. When overexpressed, the aberrant distribution of this truncated protein has an effect on the 
GTS-GFP reporter localization as these two proteins aggregate and colocalize in our model, while none of the 
other N-terminal deletion mutants produce these phenomena. In order to understand this, we analyzed trun-
cated mutants with intermediate lengths between Δ 68 and Δ 141. We also performed an alternative detection 
of myc-tagged mutants using a stable transfection system characterized by lower levels of transgene expression. 
We decided to position the starting methionines right after secondary structure features. Although the local-
ization observed for mutants Δ 95-W96M and Δ 112-N113M in the transient overexpression experiments is 
mostly nuclear and their low masses (approximately 28 and 26 kDa) are well below the exclusion limit for nuclear 
pore entry by diffusion (60 kDa)11, we did not observe that accumulation when cells were stably transfected 
(Supplementary Figure SF2). Neither aggregation nor high colocalization with GTS-GFP or GOLGA2 occurred. 
On the other hand, the distribution of Δ 122-I123M is quite similar to Δ 141 in the transient overexpression 
experiments. When the stable transfectants are analyzed, the colocalization coefficient with GOLGA2 of all four 
mutants is 0 or close to 0, clearly showing that they are not able to locate properly. Together with the immuno-
cytochemistry experiments (Supplementary Figure SF1), these results suggest that they have no activity at all. In 
conclusion, any type of mutation causing a truncation past the TM domain spoils cell surface antigen expression, 
and those N-terminal deletions reaching past codon 95 will render the encoded protein catalytically inactive.
Seltsam et al.6 showed that the allele Aw13 (2 T > C) with initiator Met codon exchanged by threonine pro-
duced a weak A phenotype and hypothesized that remaining internal methionines would be the starting amino 
acids of N-terminally truncated enzymes which in turn would be responsible for the antigen presence. In order to 
demonstrate that hypothesis, they followed a similar approach as ours but in that case they mutated sequentially 
and systematically all the ATG methionine codons to ACG encoding threonine. The results indicated that all the 
mutants, from M1T to M1,20,26,43,53,69 T had exactly the same capacity to produce A antigen on cell surfaces 
as measured by cytometry. In the light of our results, we deduced that they were essentially measuring the same 
protein, that is, an A transferase translated from the first mutated ACG codon and having the same length as the 
wild type enzyme. In this case, the additional and internal methionine to threonine mutations have apparently no 
deleterious effects. We may conclude that internal methionines are not necessary to initiate the transcription, but 
a codon similar to AUG that is close to the translational start, is. This phenomenon has been described in mam-
malian cells where certain codons differing from AUG by only one nucleotide may function as start codons12. The 
ribosome scans 5′ to 3′ from the beginning of the transcript and may choose another codon similar to AUG if the 
context is appropriate13. In fact, initiation at non-AUG codons is emerging as a new mechanism of protein expres-
sion regulation. Ingolia et al.14 characterized the abundance, type and identity of alternate open reading frames in 
mouse embryonic stem cells and have shown that a great number of alternate initiation sites are non-AUG. The 
same explanation could be extended to the mutant allele A309 (1 A > G) M1V as described above8. In the cases 
of R18X and E3X (on B allele) other AUG-like codons further down the premature stop would be responsible 
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for the translation. Indeed, the Ael/Bel phenotypes present fewer antigens than the A3 phenotype. This fact may 
respond to a longer distance of the new start codon from the original start or a less favourable sequence milieu. In 
summary, in the human context, once the canonical start codon is eliminated or the protein is early terminated, 
alternative mechanisms might act in order to allow the expression of an ABO encoded enzyme.
In vivo, inefficient translation of these mutants is probably responsible for the reduced expression of these 
proteins. Although their intrinsic activity is probably very similar to the wild-type enzyme, the amount of pro-
tein synthesized might be greatly diminished. In the case of the Aw301 allele corresponding to the M1T mutant, 
the efficiency of translation from a non-AUG start codon (ACG as we have demonstrated) produces the A weak 
phenotype which is characterized by a residual amount of A antigen present on cell surfaces. We tested this using 
two different promoters in dissimilar genomic contexts, a cytomegalovirus promoter in an episomal plasmid and 
a retroviral long terminal repeat promoter in a random genomic integration site. We obtained higher translation 
rates, allowing us to describe this phenomenon.
Methods
All the DNA constructs used in this work were prepared using standard molecular biology protocols throughout. 
After PCR amplification and cloning, Sanger sequencing was performed to check that no spurious mutations were 
introduced. Oligonucleotide sequence information is available in Supplementary Methods SM1.
Glycosyltransferase genes cloning. For the HeLa FUT2 creation, total RNA from human cell lines 
(MCF-7, MDA-MB468, MDA-MB231, BT-20 and T-47D from ATCC; #HTB-22, HTB-132, HTB-26, HTB-19, 
and HTB-133 respectively) and normal human breast epithelial cells (Cambrex) was obtained by Trizol (Life 
Technologies) extraction following manufacturer’s instructions, and pooled. Reverse transcription was performed 
with 1 μ g of total RNA using Superscript III (Invitrogen) and random primers. The resultant cDNA was used to 
clone B4GALT2 gene cDNA with oligonucleotide primers EC19/20 by PCR. FUT2 gene cDNA was amplified 
by nested PCR using the cDNA as template and oligo primers TF49(F)/TF48(R) in the first PCR and TF49(F)/
TF50(NESTED R) in the second PCR. The open reading frame of B4GALT2 was subcloned into pcDNA3.1 and 
FUT2 into pMigR1b10.
Blood group A transferase constructs. The coding sequence of A transferase or O1 protein cloned in 
pSG5 plasmid (Stratagene) was available in the laboratory as templates. Deletion constructs were obtained by 
PCR using Pfx SuperMix and custom synthesized oligo primers. The names and nucleotide sequences of prim-
ers are found in Supplementary Methods SM1. The coding sequences were cloned using EcoRI/BamHI restric-
tion sites into pSG5 vector. Their myc-tagged versions were constructed amplifying each construct using the T7 
primer and EC84 reverse primer followed by EcoRI and BamHI digestion and subcloning them into pSG5 vector.
The methionine mutants were prepared through a two-round PCR amplification using specific primers with 
nucleotide substitutions. In brief, the N-ter and C-ter DNA fragments containing nucleotide substitutions at one 
end were separately amplified in the initial round of PCR. Then those two PCR reaction products overlapping 
at the mutation site were mixed, and a secondary round of PCR was performed to amplify full-length DNA 
fragments.
The constructs needed for cytometry analysis were constructed by PCR amplification using T7 and primer 
EC110 and the truncated A transferases and threonine mutants in pSG5 plasmids as templates. After digesting 
with EcoRI, the fragments were subcloned into the same site of pMigR1g. Orientation of the inserts was checked 
by restriction analysis.
For the stably transfected cells used in the subcellular localization experiments, we modified the pMigR1g 
retroviral vector. We introduced a BamHI site using an oligo containing it at 3′ of the EcoRI site (oligonucleotide 
IM927) that was used to amplify the portion of the vector between the EcoRI and NcoI sites (with oligonucleotide 
IM928). Then the amplicon cut with these enzymes was used to replace the corresponding fragment of pMigR1g 
vector resulting in the pMigR2g vector. EcoRI and BamHI sites were used to directly sublcone the myc-tagged 
constructs from pSG5 vector into the new pMigR2g.
GTS-GFP. Golgi Targeting Sequence–GFP (GTS-GFP) was created by amplifying GFP cDNA sequence 
by PCR using oligonucleotides EC111/EC112 and pMigR1 as template. The resulting fragment was cut with 
NheI/XhoI and subcloned into the pcDNA3.1-B4GALT2 plasmid also cut with the same restriction enzymes. The 
resulting plasmid codifies for the first 60 amino acids of β 1,4-galactosyltransferase 2, known to direct the protein 
to the Golgi apparatus, followed in frame by the GFP sequence. The GTS-GFP was subcloned into the XhoI site of 
pRK5 vector by PCR amplification using oligos EC99/EC112 and restriction. Appropriate clones that contained 
the coding sequence in the correct orientation were selected.
DNA purification. Plasmids were amplified in TOP10 cells and Midiprep DNA was performed using Life 
Technologies PureLink Filter Midiprep Kit.
Cell stable transduction and culture. HeLa cells (ATCC #CCL-2) were transduced with human 
FUT2-IRES-mTagBFP retrovirus followed by FACS isolation as described in Cid et al.10 and named HeLa FUT2. 
Similarly, HeLa FUT2 cells were transduced stably with A myc-tagged mutants subcloned in pMigR2g for the 
subcellular localization experiments detailed in Fig. 5. For the N-terminal amino acid sequence determination 
MigR1-A and pMigR1-STOP-A-M1,20,26,43,53,69 T were transduced following the same strategy. Cells were 
maintained in a 5% CO2 incubator at 37 °C in Dulbecco’s Modified Eagle’s Medium (DMEM) with 10% fetal 
bovine serum (FBS) and streptomycin/penicillin.
www.nature.com/scientificreports/
1 1Scientific RepoRts | 7:41720 | DOI: 10.1038/srep41720
DNA transfection. For overexpression subcellular localization experiments, myc-tagged N-terminal trun-
cated A transferase constructs were transfected, together with GTS-GFP, in HeLa FUT2 cells plated in 8-well 
chambers (EZ slide Millipore) using Lipofectamine 2000 reagent in OPTI-MEM medium following the pro-
tocol provided by the manufacturer (Life Technologies). Transfection medium was replaced after 15 h with 
DMEM + 10% FBS and 24 h after transfection the cells were fixed with 4% paraformaldehyde, and washed exten-
sively with PBS.
For cytometry analysis HeLa FUT2 cells were seeded in 35 mm culture dishes (6.5 × 105 cells per dish) the day 
before transfection. Following the manufacturer’s protocol Lipofectamine 2000 and OPTI-MEM medium were 
used for transfection. 12 h later the medium was replaced with DMEM + 10% FBS and were maintained in a CO2 
incubator for one or two more days. Before immunostaining cells were washed with PBS and detached from the 
plate using 5 mM EDTA in PBS.
Immunostaining. For subcellular localization experiments, cells grown on glass coverslips precoated with 
100 μ g/ml poly-d-lysine were permeabilized for 10 min with PBS plus 0.2% Triton X-100 and blocked using PBS 
plus 3% Bovine Serum Albumin (BSA) and 0.2% Triton X-100 for 20 min. In the case of cells transiently overex-
pressing myc-tagged proteins, immunostaining was performed using a mouse monoclonal antibody against the 
myc epitope (9E10 from Merck Millipore) and AlexaFluor-568 anti-mouse IgG antibody (Life Technologies), 
both diluted in PBS with 1% BSA. The coverslips were mounted with ProLong Antifade Gold (Life Technologies). 
For cells stably expressing the myc-tagged proteins the same α -myc antibody was combined with a rabbit 
anti-GOLGA2 (Elabscience), and the secondary detection was performed using AlexaFluor-568 anti-mouse IgG 
and AlexaFluor-647 anti rabbit IgG (Life Technologies).
Cells destined to cytometry analysis were maintained at 4 °C during the whole procedure. First they were 
centrifuged at 500× g for 5 min and EDTA-PBS was removed. Their unspecific binding sites were blocked with 
PBS plus 1% BSA for 30 min, primary antibody (anti-A and anti-B mouse IgM from Ortho Clinical Diagnostics 
at 5-fold dilution) was added in the same buffer and incubated for 1 h, followed by two washes with PBS with 1% 
BSA using the same centrifugation settings, then by incubation with the secondary antibody (AlexaFluor-647 
anti-mouse IgM from Life Technologies) followed by two washes. Cells were resuspended in PBS prior to analysis.
SDS-polyacrylamide gel electrophoresis and immunoblotting. Standard protocols were used for 
SDS-polyacrylamide gel electrophoresis (SDS-PAGE) and immunoblotting using acrylamide/bis-acrylamide 
29:1 and Immobilon-P membrane (Millipore). Western blot was performed using TBS with 1% Triton X-100 
for washes, blocked with TBS plus 1% Triton X-100 and 3% Non-fat dry milk and incubated with anti-myc 
9E10 clone at 1/1000 in the same solution followed by washes and incubation with anti-mouse IgG-HRP anti-
body at 1/1000 (Dako). After 5 washes, the membrane was incubated with ECL substrate and photosensitive film 
was exposed to the emitted chemiluminescence. Film was developed using an automated FUJI Medical Film 
FPM100A processor.
Cytometry. For sorting (FUT2 and myc-tagged A and STOP-A-M1,20,26,43,53,69 T), cells were resuspended 
in DMEM supplemented with 2% FBS and streptomycin/penicillin and sorted using a FACS Aria II sorter (BD 
Bioscience). For the detection of A antigen on cell surface, cells were resuspended in PBS, and a FortessaLSR 
cytometer (BD Bioscience) was used for fluorescence detection. Results were recorded and analyzed with BD 
FACSDiva software and plotted using FlowJo.
Microscopy and colocalization quantification. Confocal microscopy was used to determine the sub-
cellular localization of myc-tagged constructs and their degree of colocalization with GTS-GFP or GOLGA2. 
Only one optical plane image was obtained per field and colocalization analysis was performed using the ZEN2 
software and the weighted colocalization coefficient for the myc signal channel versus the Golgi localized GFP/
GOLGA2 channel logged. Confocal images were obtained using a LSM710 AxioObserver Zeiss microscope and a 
Zeiss Plan-Apochromat 63x/1.40 oil DIC M27 objective. At least 50 cells were analyzed for each construct.
Statistical analysis. Median fluorescence calculation and significance analysis (Duncan test) were per-
formed using the R statistical program (version 3.1.0). Each construct was tested at least 4 times.
For the colocalization analysis, the data obtained by the Zen2 software was also introduced in the R program 
and boxplots and median calculations obtained. At least 50 cells for each construct were analyzed.
Affinity purification and N-terminal sequencing. Cells were lysed using TBS with 1% Triton X-100 plus 
Mini protease inhibitor cocktail (Roche) and 1 mM PMSF. After keeping the extract on ice for 15 min it was son-
icated using an Omni-Ruptor 4000 sonicator at output 3, for 1 min at 50% intermittence (OMNI International). 
The extract was then centrifuged at 15,000× g speed in a Sorvall RC6 + centrifuge and the pellet discarded. A 
Bio-Rad Poly-Prep chromatography column was packed with anti-myc agarose resin (Thermo Scientific) and pre-
washed with TBS. The clarified extract was recycled through the resin multiple times. The resin was washed with 
20 volumes of TBS+1% Triton X-100 and with 20 more volumes of TBS and eluted with 1 mg/ml myc peptide 
solution in TBS (Biotool.com). The eluted fraction was concentrated using an Amicon centrifugal device. After 
gel electrophoresis and blotting, the membrane was stained with Ponceau S and dried. The band corresponding 
to the selected protein was excised using a scalpel and sent to the Protein Chemistry Service of the Centro de 
Investigaciones Biológicas of Consejo Superior de Investigaciones Científicas, Madrid, Spain, where N-terminal 
sequence determination was performed using a Procise 494 analyzer (Thermo Scientific).
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